Brokers Set Expectations for ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Research analysts at Zacks Research raised their Q2 2025 earnings per share estimates for ResMed in a note issued to investors on Tuesday, November 12th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $2.24 per share for the quarter, up from their previous estimate of $2.19. The consensus estimate for ResMed’s current full-year earnings is $9.22 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.27 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $9.06 EPS, Q2 2026 earnings at $2.32 EPS, Q3 2026 earnings at $2.47 EPS, Q4 2026 earnings at $2.48 EPS, FY2026 earnings at $9.52 EPS and FY2027 earnings at $10.46 EPS.

Other equities analysts also recently issued reports about the stock. Baird R W upgraded shares of ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. KeyCorp upped their price objective on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Bank of America lifted their target price on shares of ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Friday, October 25th. Finally, StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average target price of $225.70.

ResMed Stock Down 4.8 %

ResMed stock opened at $235.44 on Thursday. ResMed has a fifty-two week low of $144.29 and a fifty-two week high of $260.49. The firm has a market capitalization of $34.56 billion, a price-to-earnings ratio of 31.18, a price-to-earnings-growth ratio of 1.81 and a beta of 0.69. The stock’s fifty day moving average is $243.48 and its two-hundred day moving average is $223.28. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.64 earnings per share.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed’s payout ratio is 28.08%.

Insider Buying and Selling

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the sale, the director now owns 83,204 shares of the company’s stock, valued at $20,696,162.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the transaction, the director now owns 83,204 shares of the company’s stock, valued at approximately $20,696,162.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Michael J. Rider sold 882 shares of ResMed stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the sale, the general counsel now owns 10,512 shares in the company, valued at $2,428,272. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,260 shares of company stock valued at $14,887,967. Corporate insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On ResMed

Large investors have recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of ResMed by 1.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 3,188 shares of the medical equipment provider’s stock worth $631,000 after purchasing an additional 60 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of ResMed by 88.8% during the first quarter. Empowered Funds LLC now owns 2,764 shares of the medical equipment provider’s stock valued at $547,000 after acquiring an additional 1,300 shares during the period. Concurrent Investment Advisors LLC bought a new position in shares of ResMed during the first quarter worth about $234,000. Sei Investments Co. increased its holdings in shares of ResMed by 12.9% in the 1st quarter. Sei Investments Co. now owns 21,708 shares of the medical equipment provider’s stock worth $4,299,000 after acquiring an additional 2,484 shares during the period. Finally, QRG Capital Management Inc. bought a new stake in ResMed in the 1st quarter valued at about $245,000. 54.98% of the stock is currently owned by institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.